A new study by The University of Texas Health Science Center at Houston (UTHealth) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) published in PLOS ONE by Alessandro Vespignani Ph. D. and colleagues indicates that gut bacteria and the gut microbiome are connected in a molecular network. Their findings suggest potential therapeutic approaches for preventing autoimmune diseases leading to improved quality of life in autoimmune-prone patients.

Formations of the gut microbiome and microbial symbiosis are required to sustain cellular function. Microbial species are transferred from the blood or feces and colonies of bacteria are developed in a process known as phagocytosis which is required to support physiological function. These biochemical compounds and metabolites with their bacterial DNA molecules in order to retain their gene expression are of major importance in this phagocytosis process. According to scientists from UTHealth these metabolites were originally isolated from patients with type 1 diabetes and represent a potential therapeutic target to enhance the health of patients by reducing the burden of type 1 diabetes.